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CONCLUSIONS
This study shows that as volume shifted from CABG to
PCI from 1997 to 2006, expected mortality increased for
both procedures. In-hospital mortality decreased markedly
for CABG and remained stable for PCI, leading to a smaller
mortality gap for the 2 interventions in 2006. The need for
repeat revascularization decreased, but remained signifi-
cantly higher for PCI compared with CABG. During the first
year after the index procedure, the risk of acute MI or need
for repeat CABG was also higher for PCI. Overall, RAMR
decreased for patients undergoing coronary revasculariza-
tion procedures in California from 1997 to 2006. However,
late procedure failure has persisted, especially for PCI.
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Dr Gabrial Aldea (Seattle, Wash). Decreased CABG mortality
despite increased patient acuity and complexity over the past de-
cades is indisputable and laudable. These findings were previously
published by the authors. Parallel national trends presented at this
meeting reviewing the national inpatient sample, the Society of
Thoracic Surgeons database, our own state of Washington Clinical
Outcomes Assessment Program database with more than 160,000
patients treated in the past decade, which incidentally does combineThe Journal of Thoracic and Caall CABG and PCI procedures in a single database, and those of
other multiple states. Also indisputable is the increase in the num-
ber of PCI procedures and the increasing ratio of PCI to CABG over
the same decade. I have no issues with the data, but I do have some
issues with the interpretation of the data or the suggestion that this
narrow gap will somehow influence treatment assignment. I have
several comments and 2 questions.
Despite the marked change in treatment that continues unabated
after the introduction of bare metal stents and certainly preceding
drug-eluting stents, PCI and CABG still treat very different popu-
lations. In the State of Washington for CABG, more than 95% of
the patients treated with coronary bypass surgery have 3-vessel dis-
ease of the left main and the average number of grafts is 3.4 grafts
per patient. This is compared with only 15% of patients treated with
PCI presenting with 3-vessel disease of the left main, and the aver-
age number of vessels is 1.2. Assignment to PCI and CABG sur-
gery is also changing over this time period. Acute MI therapy has
evolved dramatically in the last several years, preferentially treating
acute MIs with immediate (so-called primary) PCI rather than lytic
therapy or CABG, specifically targeting 1 and rarely 2 culprit le-
sions with a specific more limited or focused treatment strategy
to minimize the morbidity of the acute MI rather than achieve com-
plete revascularization. In fact, in our own database, acute MI ther-
apy represents 30% of all PCIs, and that is a growing incidence.
Finally, medical therapy and perhaps the biology of disease have
also evolved dramatically over this period of time with the introduc-
tion of statins, more effective and more routine antiplatelet therapy,
and stricter more effective glycemic diabetic control, decreasing the
morbidity andperhaps the incidence of somesubsets of this condition.
Given these observations, I have 2 questions for you. Given the
current approach for target lesion revascularization, particularly in
unstable angina or acute MI, is it not expected that mortality rates
for PCI and specifically reintervention rates either on the same or
untreated vessels should increase? The correlation to this question
is whether a patient who presents for repeat intervention 90 days
after an acute MI really represents a true failure rate? Is the risk
at reintervention not lower?
Dr Carey. The answer is that we had to lump everything to-
gether for the PCIs, and so the number of reinterventions is proba-
bly closer to half. It was not going to be easy to subset patients in
this kind of a database, so we simply lumped them all together.
We do understand that the PCI group is a lower risk group because
of some of the factors that you mentioned, but we just thought it
was interesting that despite the similar mortality rates, at least the
early risk of any of these procedures is basically the same, and of
course this has been reported by other groups as well.
Dr Aldea.The second question I have for you is, I expect the state
or national observed/expected ratios to be equal to 1. Yours are not.
Is it appropriate therefore to generate a combinedmodel for PCI and
CABGbased on the last 2 years, 2005 and 2006, and retrospectively
apply them to the entire cohort? This gives a significant discrepancy
between the observed and the predicted or risk-adjusted mortality.
This can artificially create what I call the Garrison Keillor Lake
Wobegon principle, wherein all men are strong and all children
above average. Your predictive model actually predicts the ob-
served/expected ratios accurately only for the last 2 years.
Dr Carey. The reason we did it this way, and of course I have 2
PhDs working on this (and they tend to confuse me daily with theirrdiovascular Surgery c Volume 138, Number 5 1105
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time, was to use 1 risk model over the entire 10-year period. It
would have seemed to me to do a different risk model for each
year, but then the years would not have been comparable. We
were trying to show the difference between PCI and CABG over
time rather than the actual specific differences between certain
groups of patients undergoing PCI and CABG.
Dr David Follette (Sacramento, Calif). Joe, I rise to congratu-
late on an extremely well presented study and to point out to the au-
dience that Dr Carey was head of the California STS for more than
20 years and worked closely with past-president Dr Harlan in 2000
for his presidential address and his 2 associates, Dr George Miller
and Dr ______, and has made a huge contribution and dedication of
his time and effort to a system that without his leadership, Califor-
nia would be in a lot worse shape in terms of the reporting of the
data. I rise to thank you, Joe, for those 20 years of diligence and
working with our other colleagues.
We are only looking at a small segment ofwhat is being done.We
are looking at isolated coronary bypass. Thus, I have 1 important
question. Is there any way that you have looked at the addition of
other procedures, such as an isolated mitral valve ring, in a high-
risk patient who has modest or mild mitral regurgitation that may
put somebody that was a high-risk patient in a different group that
you are not looking at. Is there any way in our current state of affairs
we can see if there has been a trend to add to the coronary bypass
surgery to shift them out of the reporting group into another group?
Dr Carey. It can be done. I am not sure how well we could sub-
set patients using this administrative database. We can probably do
it in the state public database because the public report, although it
only reports isolated CABG, requires all CABG procedures to be
reported to the state. There is a move afoot to do some work on
the nonisolated CABG procedures. Of course we are only collect-
ing 54 elements for risk factors in the state report, and I do not know
if we would be able to subset the mitral valve cases the way you
would really need to. You would have to use the STS database
for that, but in my opinion the STS database needs a lot of work
in terms of making it accurate, because they are missing many
deaths, especially these mitral valve cases. It takes them 3 months
to die, as you well know.
Dr Joseph Cleveland (Denver, Colo). Dr Carey, I enjoyed your
talk and I wanted to get you to flush out your comments a little bit
on one of your conclusions that public reporting was efficacious be-
cause this is a 10-year cohort, but as I understand in the introduction
I think public reporting occurred only in 2003. How can you tie in
the fact that public reporting of these data may or may not have had
any potential impact in terms of decreasing observed/expected ra-
tios and things like that, particularly with the constant risk model
when it has not changed when things may have changed with the
risk of the patients? Can you comment on that?
Dr Carey. I think you are right; it is a little bit of backward think-
ing. We are waiting for our 2007 data, and it will be interesting to
see whether the numbers stay where they are or maybe even keep
going down, but this precipitous decrease in mortality statewide
has to have some explanation. We are not really changing our tech-
niques. It is pretty much the same surgeons. We have not imported
a whole new team of surgeons from New York or somewhere1106 The Journal of Thoracic and Cardiovascular Suwhere they are getting better outcomes. Just in thinking backwards
over what happens with public reporting and talking to the doctors
around the state, I do think they are being a little more careful. They
are being a little more selective, although it looks like our expected
mortality keeps going up. The other thing is in New York, the PCI
mortality is half of what it is in California. The fact that the PCI
mortality stays the same in California and stays low in New York
may be because cardiologists are more selective in New York.
This makes me think that if we had public reporting of PCI in
California, we would have lower mortality rates for PCI.
Dr Larry Cohn (Boston, Mass). I enjoyed your article. This is
the kind of information that really needs to be publicized. I noted
that one of your sponsoring groups was the Blue Cross Blue Shield.
My question to you is, have any of these data made any impact on
reimbursement for these procedures in the State of California, or
has it actually caused the payers to say you are going to have just
a limited number of PCIs, but we are not going to let you do it in
certain patients, and we think surgery is actually better in the
long run, especially with the internal thoracic bypass and this
kind of thing. Has this had any impact on the payers in terms of de-
termining who gets what or who does not get what?
Dr Carey. That is a good question. I think there is going to be
a big delay in the impact of this kind of information at the upper
echelons of these insurance companies, and this is something that
we yet to deal with. Dan Ullyot was on the board of the Blue
Shield of California Foundation, and he is the one who suggested
that we apply for funding. He might have some information
about that. I believe he is still on the board of that foundation.
I do think it is good for us to get involved with these insurance
companies so that we can help steer their thinking in what we
think is the right direction.
Unidentified Speaker. Dr Carey, this is a great study. Our state
does not have public reporting, and certainly if you publish this we
are going to follow your lead. You report high and low-volume as
greater than 100 CABG procedures per year. I am curious if you
looked at other numbers, and why did you choose 100 as a defini-
tion of high volume?
Dr Carey. We chose that number before because 100 cases per
year is 2 coronary bypass graft cases per week. That is a not a lot
obviously, but hospitals with 2 coronary bypass grafts or more
have an average volume of at least more than 200 cases per
year. Now as we are performing fewer and fewer procedures, the
definition of high volume is changing. There is an article in this
month’s Journal of Thoracic and Cardiovascular Surgery about
the volumes in Japan, where they are even lower than they are
in California. Apparently they have lots of little programs in Japan
and achieve good outcomes there, even in the lower-volume pro-
grams. High volume is really probably more than 100, but for
the purposes of our study, it splits it right in half, making a fairly
equal comparison.
Unidentified Speaker. That is interesting, because in Japan
there are typically 3 surgeons for every bypass operation, 3 cardiac
surgeons. They have somebody harvesting a vein, somebody har-
vesting a thoracic artery, and somebody actually performing the op-
eration. In fact, that is how I believe they keep their surgeon
volumes up, although their case volumes are not great.rgery c November 2009
